title: Therapeutic development in psoriasis.
abstract: Advances in molecular biology have provided the basis for development of new therapeutic approaches to psoriasis. New, more effective therapies target specific molecules in the inflammatory cascade involved in the pathogenesis of psoriasis.The biologic era of psoriasis therapy began with inhibitors of T-cell activation, tumor necrosis factor-α, and interleukin (IL)-12/23. Continued investigation has led to therapies and therapeutic candidates that target IL-17, IL-23, phosphodiesterase-4, and isomers of Janus kinase.
authors.affiliation: Assistant Professor of Dermatology, Tufts School of Medicine; Director, Psoriasis Treatment Center, Skincare Physicians, Chestnut Hill, MA.
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Sobell
authors.affiliation: Clinical Professor of Dermatology, Saint Louis University Central Dermatology, St Louis, MO.
authors.forename: Craig L
authors.initials: CL
authors.lastname: Leonardi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D053759:Interleukin-23 / Q000037:antagonists & inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D053759:Interleukin-23; D010726:Phosphodiesterase Inhibitors; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D013792:Thalidomide; C571216:brodalumab; C479163:tofacitinib; C549079:ixekizumab; C555450:secukinumab; C505730:apremilast
keywords: JAK interlukin-17 inhibitors; Janus kinase inhibitors; apremilast; brodalumab; inflammation; interleukin-12/23; ixekizumab; monoclonal antibody; phosphodiesterase-4; psoriasis; secukinumab; tofacitinib; tumor necrosis factors